Business, energy, technology, markets and global industry news from Business News Today

metabolic disease

PharmaDeviceNews metabolic disease
Representative image: Kalohexis’ 710GO obesity drug research highlights how dual MC3R/MC4R activation could reshape oral weight loss therapy beyond GLP-1 medicines.
Pharma & Biotech

Kalohexis 710GO data highlight a differentiated obesity mechanism as Phase 1 moves ahead

Read how Kalohexis’ 710GO could challenge GLP-1 obesity drugs with dual MC3R/MC4R activation, lean-mass sparing and durability.

Read More
Representative image of a clinical researcher reviewing liver imaging and lipid test results, reflecting OrsoBio’s TLC-2716 Phase 2a data in severe hypertriglyceridemia and MASLD.
Pharma & Biotech

OrsoBio’s TLC-2716 data point to a new oral route in severe metabolic lipid disease

Find out how OrsoBio’s TLC-2716 Phase 2a data could reshape severe hypertriglyceridemia and MASLD drug development.

Read More
Representative image of a clinical weight-management consultation with an injection pen and progress chart, reflecting Pfizer’s berobenatide Phase 2b data and the growing race to develop monthly GLP-1 obesity treatments.
Pharma & Biotech

Pfizer’s Phase 2b obesity data put monthly GLP-1 dosing back in investor focus

Find out how Pfizer’s berobenatide Phase 2b data could reshape monthly GLP-1 obesity treatment and late-stage trial strategy.

Read More
Representative image of a physician reviewing glucose trend data with a diabetes patient, reflecting Cirius Therapeutics’ CIR-0602K research and the growing search for new insulin-sensitizing therapies beyond GLP-1 drugs.
Pharma & Biotech

Cirius Therapeutics puts CIR-0602K in the spotlight as ADA 2026 turns to metabolic complexity

Cirius Therapeutics is pushing CIR-0602K into the ADA 2026 spotlight. Find out why insulin sensitivity may be diabetes’ next battleground.

Read More
Representative image of obesity treatment research. Kalohexis’ 710GO data highlights growing interest in dual MC3R and MC4R activation as the next frontier in weight loss drug development.
Pharma & Biotech

Kalohexis 710GO data puts melanocortin obesity drugs back in the metabolic spotlight

GLP-1 drugs dominate obesity care, but Kalohexis is testing a different pathway. 710GO could shift the next weight loss race.

Read More
Pharma & Biotech

Neurocrine’s $2.9bn Soleno deal raises the stakes in Prader-Willi syndrome treatment

Find out how Neurocrine’s $2.9bn Soleno acquisition could reshape VYKAT XR’s rare disease launch strategy.

Read More
Representative image: GSK’s $1 billion SiranBio deal highlights how oligonucleotide therapies such as SA030 could open a new front in metabolic disease research by targeting visceral fat biology beyond conventional obesity drugs.
Pharma & Biotech

GSK’s $1bn SiranBio pact raises the stakes in extrahepatic siRNA delivery

GLP-1 drugs dominate obesity. GSK is betting SiranBio’s SA030 can attack visceral fat risk from a different angle.

Read More
Medical Devices & Diagnostics

Can Anaxiom’s AVOS device open a new minimally invasive route in obesity treatment?

Find out how Anaxiom’s AVOS obesity device could reshape minimally invasive weight-loss treatment after early human results.

Read More
Pharma & Biotech

Why the Terns acquisition matters more for Merck’s long-term pipeline strategy than its near-term revenue

Merck has begun its tender offer for Terns Pharmaceuticals. Read what the deal could change for metabolic drug competition and pipeline strategy.

Read More
Pharma & Biotech

What Caliway’s CBL-514 and tirzepatide combination data could reveal about obesity treatment next

Caliway’s CBL-514 heads to ADA 2026 with tirzepatide combination data. Read what this could change in obesity treatment strategy.

Read More